Skip to content
Swedish scientists have made a groundbreaking development with a 3D-printed microscale implant designed for the eye, featuring pancreatic cells. This revolutionary device could potentially revolutionize the treatment of diabetes and various other diseases.
The research team from Sweden has successfully engineered an eye implant that provides a unique avenue for cell-based therapy, primarily targeting diabetes but also presenting possibilities for addressing other ailments. The implant permits the precise positioning of pancreatic cells in the eye, opening up new avenues for cell-based therapies.
Pancreatic islets, clusters of cells responsible for insulin production in the pancreas, were chosen as the cell source for this innovative device. Pancreatic islets have been the subject of experimental treatments for type 1 diabetes, where the immune system mistakenly attacks insulin-producing cells, leading to dysregulation of blood sugar levels.
One significant challenge associated with using donor pancreatic islets in type 1 diabetes treatments has been the need to prevent rejection by the recipient’s immune system. The Swedish researchers propose that implanting the device in the eye offers a solution due to the eye’s “immune-privileged” status. The eye can tolerate foreign substances or molecules without triggering an inflammatory immune response.
Anna Herland, a senior lecturer in the Division of Bionanotechnology at Sweden’s KTH Royal Institute of Technology and the study’s author, explained, “Donor transplants always have a degree of reaction from the immune system. As the eye does not have resident immune cells, we avoid these first reactions from the immune system.”
The device, measuring approximately 240 micrometers long, is secured between the iris and the cornea in the eye’s anterior chamber (ACE). In tests conducted on mice, the implant maintained its position for several months.
Wouter van der Wijngaart, a professor in the Division of Micro- and Nanosystems at KTH, highlighted the design’s innovative aspects, noting that they created the device “to hold living mini-organs in a micro-cage and introduced the use of a flap door technique to avoid the need for additional fixation.”
The researchers observed that these “mini-organs” swiftly integrated with the host animal’s blood vessels and functioned normally.
One remarkable aspect of this technology is its non-invasive monitoring of functionality and care. Herland stated, “Ours is a first step towards advanced medical microdevices that can both localize and monitor the function of cell grafts.”
This development marks the first instance of “mechanical fixation” of a device in the eye’s anterior chamber.
While this study serves as a proof of concept, the researchers are eager to advance this technology’s capabilities, with potential applications extending beyond diabetes treatment. Herland expressed optimism: “It can be used to host other organoid [tissue culture] like transplants. Today, diseases are not treated by organoid-like transplants except in trials with pancreatic cells, but it is possible that tissues like thyroid glands could be evaluated in the future.”
As the research progresses, it holds promise not only for diabetes patients but for those battling various other diseases, potentially offering new hope and treatment avenues.
